Related Experiment Video
Updated: Mar 26, 2026

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1
Dimitri Topalis1, Tatiane C Nogueira1, Tim De Schutter1
1Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Abstract:
Human papillomavirus (HPV) is responsible for cervical cancer, and its role in head and neck carcinoma has been reported. No drug is approved for the treatment of HPV-related diseases but cidofovir (CDV) exhibits selective antiproliferative activity. In this study, we analyzed the effects of CDV-resistance (CDVR) in two HPV(+) (SiHaCDV and HeLaCDV) and one HPV(-) (HaCaTCDV) tumor cell lines. Quantification of CDV metabolites and analysis of the sensitivity profile to chemotherapeutics was performed. Transporters expression related to multidrug-resistance (MRP2, P-gp, BCRP) was also investigated. Alterations of CDV metabolism in SiHaCDV and HeLaCDV, but not in HaCaTCDV, emerged via impairment of UMP/CMPK1 activity. Mutations (P64T and R134M) as well as down-regulation of UMP/CMPK1 expression were observed in SiHaCDV and HeLaCDV, respectively. Altered transporters expression in SiHaCDV and/or HeLaCDV, but not in HaCaTCDV, was also noted. Taken together, these results indicate that CDVR in HPV(+) tumor cells is a multifactorial process.
Insights
Cidofovir resistance in human papillomavirus-positive tumors is complex. This study reveals that altered metabolism and transporter expression contribute to cidofovir resistance in HPV(+) cancer cells.
Area of Science:
- Oncology
- Virology
- Pharmacology
Background:
- Human papillomavirus (HPV) is a key driver of cervical cancer and implicated in head and neck cancers.
- Currently, no drugs are approved for HPV-related diseases, though cidofovir (CDV) shows antiproliferative effects.
Purpose of the Study:
- To investigate the mechanisms of cidofovir resistance (CDVR) in HPV-positive (HPV(+)) and HPV-negative (HPV(-)) tumor cell lines.
- To analyze alterations in CDV metabolism, drug sensitivity, and transporter expression in CDV-resistant cells.
Main Methods:
- Cultured HPV(+) (SiHaCDV, HeLaCDV) and HPV(-) (HaCaTCDV) cell lines were developed for CDV resistance.
- Quantified CDV metabolites and assessed sensitivity to chemotherapeutics.
- Investigated the expression of multidrug-resistance transporters (MRP2, P-gp, BCRP).
Main Results:
- Impaired UMP/CMPK1 activity led to altered CDV metabolism in HPV(+) cell lines (SiHaCDV, HeLaCDV), but not in HPV(-) (HaCaTCDV).
- Specific mutations (P64T) or down-regulation of UMP/CMPK1 were observed in SiHaCDV and HeLaCDV, respectively.
- Altered expression of multidrug-resistance transporters was noted in SiHaCDV and/or HeLaCDV, but not in HaCaTCDV.
Conclusions:
- CDV resistance in HPV(+) tumor cells is a multifactorial process.
- Mechanisms include impaired CDV metabolism via UMP/CMPK1 alterations and changes in transporter expression.
- Findings provide insights into potential therapeutic strategies for HPV-related cancers.
Related Concept Videos
Inhibition of Cdk Activity
Treatment Resistant Cancers
Abnormal Proliferation
Anaphase Promoting Complex
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

